Pharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors

Advances in Pharmacology

Volumn 62, Issue , 2011, Pages 109-141

  Conn, P Michael ^a,b,c,d   Ulloa Aguirre, Alfredo ^a,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Hospital Luis Castelazo Ayala   (Mexico)

Author keywords

G protein coupled receptors; Gonadotropin releasing hormone; Gonadotropin releasing hormone receptor; Mutant rescue; Pharmacoperones; Protein misfolding

Indexed keywords

A 177775; CELL SURFACE PROTEIN; CHAPERONE; G PROTEIN COUPLED RECEPTOR; GONADORELIN RECEPTOR; IN 3; INDOLE DERIVATIVE; MACROLIDE; PEPTIDOMIMETIC AGENT; Q 89; QUINOLONE DERIVATIVE; RHODOPSIN; SCAFFOLD PROTEIN; SUFUGOLIX; UNCLASSIFIED DRUG;

BOOK; CONGENITAL HYPOTHYROIDISM; DRUG MECHANISM; DRUG TARGETING; ENDOPLASMIC RETICULUM; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; GENE MUTATION; GLUCOCORTICOSTEROID DEFICIENCY; HIRSCHSPRUNG DISEASE; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; LOSS OF FUNCTION MUTATION; MALE PSEUDOHERMAPHRODITISM; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; OBESITY; OVARY DYSGENESIS; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN LOCALIZATION; QUALITY CONTROL; RETINITIS PIGMENTOSA;

EID: 80052682475     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385952-5.00008-7     Document Type: Chapter

References (179)

1. Aittomaki K., Lucena J.L., Pakarinen P., Sistonen P., Tapanainen J., Gromoll J., et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995, 82:959-968.
2. Amaral M.D. Therapy through chaperones: Sense or antisense? Cystic fibrosis as a model disease. Journal of Inherited Metabolic Disease 2006, 29:477-487.
3. Amiel J., Sproat-Emison E., Garcia-Barcelo M., Lantieri F., Burzynski G., Borrego S., et al. Hirschsprung disease, associated syndromes and genetics: A review. Journal of Medical Genetics 2008, 45:1-14.
4. Andersson H., D'Antona A.M., Kendall D.A., Von Heijne G., Chin C.N. Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail. Molecular Pharmacology 2003, 64:570-577.
5. Angelotti T., Daunt D., Shcherbakova O.G., Kobilka B., Hurt C.M. Regulation of G-protein coupled receptor traffic by an evolutionary conserved hydrophobic signal. Traffic 2010, 11:560-578.
6. Angers S., Salahpour A., Bouvier M. Dimerization: An emerging concept for G protein-coupled receptor ontogeny and function. Annual Review of Pharmacology and Toxicology 2002, 42:409-435.
7. Angers S., Salahpour A., Joly E., Hilairet S., Chelsky D., Dennis M., et al. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proceedings of the National Academy of Sciences of the United States of America 2000, 97:3684-3689.
8. Arakawa T., Ejima D., Kita Y., Tsumoto K. Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochimica et Biophysica Acta 2006, 1764:1677-1687.
9. Armstrong S.P., Caunt C.J., Finch A.R., McArdle C.A. Using automated imaging to interrogate gonadotrophin-releasing hormone receptor trafficking and function. Molecular and Cellular Endocrinology 2011, 331:194-204.
10. Arora K.K., Chung H.O., Catt K.J. Influence of a species-specific extracellular amino acid on expression and function of the human gonadotropin-releasing hormone receptor. Molecular Endocrinology 1999, 13:890-896.
11. Ashton W.T., Sisco R.M., Kieczykowski G.R., Yang Y.T., Yudkovitz J.B., Cui J., et al. Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. Bioorganic & Medicinal Chemistry Letters 2001, 11:2597-2602.
12. Ashton W.T., Sisco R.M., Yang Y.T., Lo J.L., Yudkovitz J.B., Cheng K., et al. Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2001, 11:1723-1726.
13. Ashton W.T., Sisco R.M., Yang Y.T., Lo J.L., Yudkovitz J.B., Gibbons P.H., et al. Potent nonpeptide GnRH receptor antagonists derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side-chain terminus. Bioorganic & Medicinal Chemistry Letters 2001, 11:1727-1731.
14. Ayoub M.A., Couturier C., Lucas-Meunier E., Angers S., Fossier P., Bouvier M., et al. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. The Journal of Biological Chemistry 2002, 277:21522-21528.
15. Beaumont K.A., Newton R.A., Smit D.J., Leonard J.H., Stow J.L., Sturm R.A. Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. Human Molecular Genetics 2005, 14:2145-2154.
16. Beaumont K.A., Shekar S.N., Newton R.A., James M.R., Stow J.L., Duffy D.L., et al. Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. Human Molecular Genetics 2007, 16:2249-2260.
17. Bedecarrats G.Y., Kaiser U.B. Differential regulation of gonadotropin subunit gene promoter activity by pulsatile gonadotropin-releasing hormone (GnRH) in perifused L beta T2 cells: Role of GnRH receptor concentration. Endocrinology 2003, 144:1802-1811.
18. Benkirane M., Jin D.Y., Chun R.F., Koup R.A., Jeang K.T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. The Journal of Biological Chemistry 1997, 272:30603-30606.
19. Beranova M., Oliveira L.M., Bedecarrats G.Y., Schipani E., Vallejo M., Ammini A.C., et al. Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology and Metabolism 2001, 86:1580-1588.
20. Bernier V., Bichet D.G., Bouvier M. Pharmacological chaperone action on G-protein-coupled receptors. Current Opinion in Pharmacology 2004, 4:528-533.
21. Bernier V., Lagace M., Bichet D.G., Bouvier M. Pharmacological chaperones: Potential treatment for conformational diseases. Trends in Endocrinology and Metabolism 2004, 15:222-228.
22. Bernier V., Morello J.P., Zarruk A., Debrand N., Salahpour A., Lonergan M., et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. Journal of the American Society of Nephrology 2006, 17:232-243.
23. Bichet D.G. Nephrogenic diabetes insipidus. Néphrologie & Thérapeutique 2006, 2:387-404.
24. Biebermann H., Schoneberg T., Krude H., Schultz G., Gudermann T., Gruters A. Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism. The Journal of Clinical Endocrinology and Metabolism 1997, 82:3471-3480.
25. Blomenrohr M., Heding A., Sellar R., Leurs R., Bogerd J., Eidne K.A., et al. Pivotal role for the cytoplasmic carboxyl-terminal tail of a nonmammalian gonadotropin-releasing hormone receptor in cell surface expression, ligand binding, and receptor phosphorylation and internalization. Molecular Pharmacology 1999, 56:1229-1237.
26. Bouvier M. Oligomerization of G-protein-coupled transmitter receptors. Nature Reviews. Neuroscience 2001, 2:274-286.
27. Broadley S.A., Hartl F.U. The role of molecular chaperones in human misfolding diseases. FEBS Letters 2009, 583:2647-2653.
28. Brooks D.A. Introduction: Molecular chaperones of the ER: Their role in protein folding and genetic disease. Seminars in Cell & Developmental Biology 1999, 10:441-442.
29. Brothers S.P., Cornea A., Janovick J.A., Conn P.M. Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: Molecular basis of the dominant-negative effect. Molecular Endocrinology 2004, 18:1787-1797.
30. Brothers S.P., Janovick J.A., Conn P.M. Unexpected effects of epitope and chimeric tags on gonadotropin-releasing hormone receptors: Implications for understanding the molecular etiology of hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology and Metabolism 2003, 88:6107-6112.
31. Brothers S.P., Janovick J.A., Conn P.M. Calnexin regulated gonadotropin-releasing hormone receptor plasma membrane expression. Journal of Molecular Endocrinology 2006, 37:479-488.
32. Brown C.R., Hong-Brown L.Q., Welch W.J. Strategies for correcting the delta F508 CFTR protein-folding defect. Journal of Bioenergetics and Biomembranes 1997, 29:491-502.
33. Bulenger S., Marullo S., Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends in Pharmacological Sciences 2005, 26:131-137.
34. Butters T.D. Gaucher disease. Current Opinion in Chemical Biology 2007, 11:412-418.
35. Butters T.D. Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders. Expert Opinion on Pharmacotherapy 2007, 8:427-435.
36. Calebiro D., de Filippis T., Lucchi S., Covino C., Panigone S., Beck-Peccoz P., et al. Intracellular entrapment of wild-type TSH receptor by oligomerization with mutants linked to dominant TSH resistance. Human Molecular Genetics 2005, 14:2991-3002.
37. Castro-Fernandez C., Maya-Nunez G., Conn P.M. Beyond the signal sequence: Protein routing in health and disease. Endocrine Reviews 2005, 26:479-503.
38. Clark P.L. Protein folding in the cell: Reshaping the folding funnel. Trends in Biochemical Sciences 2004, 29:527-534.
39. Clark A.J., Metherell L.A., Cheetham M.E., Huebner A. Inherited ACTH insensitivity illuminates the mechanisms of ACTH action. Trends in Endocrinology and Metabolism 2005, 16:451-457.
40. Conn P.M. Recue of gonadotropin hormone receptor mutants 2010, US7,695,917.
41. Conn P.M., Crowley W.F. Gonadotropin-releasing hormone and its analogs. Annual Review of Medicine 1994, 45:391-405.
42. Conn P.M., Janovick J.A. Drug development and the cellular quality control system. Trends in Pharmacological Sciences 2009, 30:228-233.
43. Conn P.M., Janovick J.A. Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Molecular and Cellular Endocrinology 2009, 299:137-145.
44. Conn P.M., Janovick J.A., Brothers S.P., Knollman P.E. 'Effective inefficiency': Cellular control of protein trafficking as a mechanism of post-translational regulation. The Journal of Endocrinology 2006, 190:13-16.
45. Conn P.M., Knollman P.E., Brothers S.P., Janovick J.A. Protein folding as posttranslational regulation: Evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor. Molecular Endocrinology 2006, 20:3035-3041.
46. Conn P.M., Leanos-Miranda A., Janovick J.A. Protein origami: Therapeutic rescue of misfolded gene products. Molecular Interventions 2002, 2:308-316.
47. Conn P.M., Ulloa-Aguirre A. Trafficking of G-protein-coupled receptors to the plasma membrane: Insights for pharmacoperone drugs. Trends in Endocrinology and Metabolism 2010, 21:190-197.
48. Conn P.M., Ulloa-Aguirre A., Ito J., Janovick J.A. G protein-coupled receptor trafficking in health and disease: Lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacological Reviews 2007, 59:225-250.
49. Cook L.B., Zhu C.C., Hinkle P.M. Thyrotropin-releasing hormone receptor processing: Role of ubiquitination and proteasomal degradation. Molecular Endocrinology 2003, 17:1777-1791.
50. Cornea A., Janovick J.A., Maya-Nunez G., Conn P.M. Gonadotropin-releasing hormone receptor microaggregation. Rate monitored by fluorescence resonance energy transfer. The Journal of Biological Chemistry 2001, 276:2153-2158.
51. de Roux N., Milgrom E. Inherited disorders of GnRH and gonadotropin receptors. Molecular and Cellular Endocrinology 2001, 179:83-87.
52. Dong C., Filipeanu C.M., Duvernay M.T., Wu G. Regulation of G protein-coupled receptor export trafficking. Biochimica et Biophysica Acta 2007, 1768:853-870.
53. Dormer R.L., Derand R., McNeilly C.M., Mettey Y., Bulteau-Pignoux L., Metaye T., et al. Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. Journal of Cell Science 2001, 114:4073-4081.
54. D'Souza-Li L., Yang B., Canaff L., Bai M., Hanley D.A., Bastepe M., et al. Identification and functional characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. The Journal of Clinical Endocrinology and Metabolism 2002, 87:1309-1318.
55. Dunham J.H., Hall R.A. Enhancement of the surface expression of G protein-coupled receptors. Trends in Biotechnology 2009, 27:541-545.
56. Ellgaard L., Helenius A. Quality control in the endoplasmic reticulum. Nature Reviews. Molecular Cell Biology 2003, 4:181-191.
57. Ellis R.J. Protein misassembly: Macromolecular crowding and molecular chaperones. Advances in Experimental Medicine and Biology 2007, 594:1-13.
58. Englander S.W., Mayne L., Krishna M.M. Protein folding and misfolding: Mechanism and principles. Quarterly Reviews of Biophysics 2007, 40:287-326.
59. Fan Z.C., Tao Y.X. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. Journal of Cellular and Molecular Medicine 2009, 13:3268-3282.
60. Fan J.-Q., Valenzano K., Lee G., Bouvier M. Pharmacological chaperones for treating obesity 2009, US Patent application number 20090312345.
61. Ferris H.A., Shupnik M.A. Mechanisms for pulsatile regulation of the gonadotropin subunit genes by GNRH1. Biology of Reproduction 2006, 74:993-998.
62. Finch A.R., Caunt C.J., Armstrong S.P., McArdle C.A. Plasma membrane expression of gonadotropin-releasing hormone receptors: Regulation by peptide and nonpeptide antagonists. Molecular Endocrinology 2010, 24:423-435.
63. Fuchs S., Amiel J., Claudel S., Lyonnet S., Corvol P., Pinet F. Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirschsprung's disease: Evidence for selective loss of Gi coupling. Molecular Medicine 2001, 7:115-124.
64. Fujiwara T.M., Bichet D.G. Molecular biology of hereditary diabetes insipidus. Journal of the American Society of Nephrology 2005, 16:2836-2846.
65. Galietta L.J., Springsteel M.F., Eda M., Niedzinski E.J., By K., Haddadin M.J., et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. The Journal of Biological Chemistry 2001, 276:19723-19728.
66. Gehret A.U., Bajaj A., Naider F., Dumont M.E. Oligomerization of the yeast alpha-factor receptor: Implications for dominant negative effects of mutant receptors. The Journal of Biological Chemistry 2006, 281:20698-20714.
67. Gorbatyuk M.S., Knox T., LaVail M.M., Gorbatyuk O.S., Noorwez S.M., Hauswirth W.W., et al. Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:5961-5966.
68. Gromoll J., Schulz A., Borta H., Gudermann T., Teerds K.J., Greschniok A., et al. Homozygous mutation within the conserved Ala-Phe-Asn-Glu-Thr motif of exon 7 of the LH receptor causes male pseudohermaphroditism. European Journal of Endocrinology 2002, 147:597-608.
69. Guo W., Shi L., Javitch J.A. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. The Journal of Biological Chemistry 2003, 278:4385-4388.
70. Hague C., Uberti M.A., Chen Z., Hall R.A., Minneman K.P. Cell surface expression of alpha1D-adrenergic receptors is controlled by heterodimerization with alpha1B-adrenergic receptors. The Journal of Biological Chemistry 2004, 279:15541-15549.
71. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: From nascent chain to folded protein. Science 2002, 295:1852-1858.
72. Hartl F.U., Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. Nature Structural & Molecular Biology 2009, 16:574-581.
73. Heding A., Vrecl M., Bogerd J., McGregor A., Sellar R., Taylor P.L., et al. Gonadotropin-releasing hormone receptors with intracellular carboxyl-terminal tails undergo acute desensitization of total inositol phosphate production and exhibit accelerated internalization kinetics. The Journal of Biological Chemistry 1998, 273:11472-11477.
74. Helenius A. Quality control in the secretory assembly line. Philosophical Transactions of the Royal Society of London, Series B, Biological Sciences 2001, 356:147-150.
75. Hermosilla R., Oueslati M., Donalies U., Schonenberger E., Krause E., Oksche A., et al. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 2004, 5:993-1005.
76. Herrick-Davis K., Grinde E., Mazurkiewicz J.E. Biochemical and biophysical characterization of serotonin 5-HT2C receptor homodimers on the plasma membrane of living cells. Biochemistry 2004, 43:13963-13971.
77. Huang Y., Breitwieser G.E. Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. The Journal of Biological Chemistry 2007, 282:9517-9525.
78. Huhtaniemi I.T., Themmen A.P. Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine 2005, 26:207-217.
79. Illing M.E., Rajan R.S., Bence N.F., Kopito R.R. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. The Journal of Biological Chemistry 2002, 277:34150-34160.
80. Janovick J.A., Brothers S.P., Cornea A., Bush E., Goulet M.T., Ashton W.T., et al. Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro. Molecular and Cellular Endocrinology 2007, 272:77-85.
81. Janovick J.A., Brothers S.P., Knollman P.E., Conn P.M. Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand. The FASEB Journal 2007, 21:384-392.
82. Janovick J.A., Conn P.M. Salt bridge integrates GPCR activation with protein trafficking. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:4454-4458.
83. Janovick J.A., Goulet M., Bush E., Greer J., Wettlaufer D.G., Conn P.M. Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. The Journal of Pharmacology and Experimental Therapeutics 2003, 305:608-614.
84. Janovick J.A., Knollman P.E., Brothers S.P., Ayala-Yanez R., Aziz A.S., Conn P.M. Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: Molecular basis of an evolved strategy. The Journal of Biological Chemistry 2006, 281:8417-8425.
85. Janovick J.A., Maya-Nunez G., Conn P.M. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: Misrouted proteins as a novel disease etiology and therapeutic target. The Journal of Clinical Endocrinology and Metabolism 2002, 87:3255-3262.
86. Janovick J.A., Patney A., Mosely R., Goulet M., Altman M., Rush T., et al. Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: The GnRH receptor. Molecular Endocrinology 2009, 23:157-168.
87. Janovick J.A., Ulloa-Aguirre A., Conn P.M. Evolved regulation of gonadotropin-releasing hormone receptor cell surface expression. Endocrine 2003, 22:317-327.
88. Jardon-Valadez E., Aguilar-Rojas A., Maya-Nunez G., Leanos-Miranda A., Pineiro A., Conn P.M., et al. Conformational effects of Lys191 in the human gonadotrophin-releasing hormone receptor (hGnRHR). Mutagenesis and molecular dynamics simulations studies. The Journal of Endocrinology 2009, 201:297-307.
89. Jardon-Valadez E., Ulloa-Aguirre A., Pineiro A. Modeling and molecular dynamics simulation of the human gonadotropin-releasing hormone receptor in a lipid bilayer. The Journal of Physical Chemistry B 2008, 112:10704-10713.
90. Jennes L., Ulloa-Aguirre A., Janovick J., Adjan V., Conn P.M. Gonadotropin releasing hormone and its receptor. Hormones, Brain and Behavior, (2nd ed.) 3, 1645-1668 2009, Academic Press, New York. D.W. Pfaff, A.P. Arnold, A.M. Etgen, S.E. Fahrbach, R.T. Rubin (Eds.).
91. Kaiser U.B., Conn P.M., Chin W.W. Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocrine Reviews 1997, 18:46-70.
92. Katada S., Tanaka M., Touhara K. Structural determinants for membrane trafficking and G protein selectivity of a mouse olfactory receptor. Journal of Neurochemistry 2004, 90:1453-1463.
93. Kato A., Touhara K. Mammalian olfactory receptors: Pharmacology, G protein coupling and desensitization. Cellular and Molecular Life Sciences 2009, 66:3743-3753.
94. Kaupmann K., Malitschek B., Schuler V., Heid J., Froestl W., Beck P., et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 1998, 396:683-687.
95. Knobil E. On the control of gonadotropin secretion in the rhesus monkey. Recent Progress in Hormone Research 1974, 30:1-46.
96. Knollman P.E., Janovick J.A., Brothers S.P., Conn P.M. Parallel regulation of membrane trafficking and dominant-negative effects by misrouted gonadotropin-releasing hormone receptor mutants. The Journal of Biological Chemistry 2005, 280:24506-24514.
97. Krsmanovic L.Z., Hu L., Leung P.K., Feng H., Catt K.J. The hypothalamic GnRH pulse generator: Multiple regulatory mechanisms. Trends in Endocrinology and Metabolism 2009, 20:402-408.
98. Krsmanovic L.Z., Hu L., Leung P.K., Feng H., Catt K.J. Pulsatile GnRH secretion: Roles of G protein-coupled receptors, second messengers and ion channels. Molecular and Cellular Endocrinology 2010, 314:158-163.
99. Lagerstrom M.C., Schioth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nature Reviews. Drug Discovery 2008, 7:339-357.
100. Le Gouill C., Parent J.L., Caron C.A., Gaudreau R., Volkov L., Rola-Pleszczynski M., et al. Selective modulation of wild type receptor functions by mutants of G-protein-coupled receptors. The Journal of Biological Chemistry 1999, 274:12548-12554.
101. Leandro P., Gomes C.M. Protein misfolding in conformational disorders: Rescue of folding defects and chemical chaperoning. Mini Reviews in Medicinal Chemistry 2008, 8:901-911.
102. Leanos-Miranda A., Janovick J.A., Conn P.M. Receptor-misrouting: An unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology and Metabolism 2002, 87:4825-4828.
103. Leanos-Miranda A., Ulloa-Aguirre A., Janovick J.A., Conn P.M. In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles. The Journal of Clinical Endocrinology and Metabolism 2005, 90:3001-3008.
104. Leanos-Miranda A., Ulloa-Aguirre A., Ji T.H., Janovick J.A., Conn P.M. Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: A trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans. The Journal of Clinical Endocrinology and Metabolism 2003, 88:3360-3367.
105. Lee S.P., O'Dowd B.F., Ng G.Y., Varghese G., Akil H., Mansour A., et al. Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell. Molecular Pharmacology 2000, 58:120-128.
106. Leskela T.T., Markkanen P.M., Pietila E.M., Tuusa J.T., Petaja-Repo U.E. Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum. The Journal of Biological Chemistry 2007, 282:23171-23183.
107. Lieberman R.L., Wustman B.A., Huertas P., Powe A.C., Pine C.W., Khanna R., et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nature Chemical Biology 2007, 3:101-107.
108. Lim S., Pnueli L., Tan J.H., Naor Z., Rajagopal G., Melamed P. Negative feedback governs gonadotrope frequency-decoding of gonadotropin releasing hormone pulse-frequency. PLoS One 2009, 4:e7244.
109. Lin X., Janovick J.A., Brothers S., Blomenrohr M., Bogerd J., Conn P.M. Addition of catfish gonadotropin-releasing hormone (GnRH) receptor intracellular carboxyl-terminal tail to rat GnRH receptor alters receptor expression and regulation. Molecular Endocrinology 1998, 12:161-171.
110. Loo T.W., Clarke D.M. Chemical and pharmacological chaperones as new therapeutic agents. Expert Reviews in Molecular Medicine 2007, 9:1-18.
111. Lu M., Echeverri F., Moyer B.D. Endoplasmic reticulum retention, degradation, and aggregation of olfactory G-protein coupled receptors. Traffic 2003, 4:416-433.
112. Lu M., Staszewski L., Echeverri F., Xu H., Moyer B.D. Endoplasmic reticulum degradation impedes olfactory G-protein coupled receptor functional expression. BMC Cell Biology 2004, 5:34.
113. Margeta-Mitrovic M. Assembly-dependent trafficking assays in the detection of receptor-receptor interactions. Methods 2002, 27:311-317.
114. Margeta-Mitrovic M., Jan Y.N., Jan L.Y. A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron 2000, 27:97-106.
115. Martens J.W., Lumbroso S., Verhoef-Post M., Georget V., Richter-Unruh A., Szarras-Czapnik M., et al. Mutant luteinizing hormone receptors in a compound heterozygous patient with complete Leydig cell hypoplasia: Abnormal processing causes signaling deficiency. The Journal of Clinical Endocrinology and Metabolism 2002, 87:2506-2513.
116. Maya-Nunez G., Janovick J.A., Aguilar-Rojas A., Jardon-Valadez E., Leanos-Miranda A., Zarinan T., et al. Biochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadism. Molecular and Cellular Endocrinology 2011, 337:16-23.
117. Maya-Nunez G., Janovick J.A., Conn P.M. Combined modification of intracellular and extracellular loci on human gonadotropin-releasing hormone receptor provides a mechanism for enhanced expression. Endocrine 2000, 13:401-407.
118. Maya-Nunez G., Janovick J.A., Ulloa-Aguirre A., Soderlund D., Conn P.M., Mendez J.P. Molecular basis of hypogonadotropic hypogonadism: Restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site. The Journal of Clinical Endocrinology and Metabolism 2002, 87:2144-2149.
119. McArdle C.A., Davidson J.S., Willars G.B. The tail of the gonadotrophin-releasing hormone receptor: Desensitization at, and distal to, G protein-coupled receptors. Molecular and Cellular Endocrinology 1999, 151:129-136.
120. McVey M., Ramsay D., Kellett E., Rees S., Wilson S., Pope A.J., et al. Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. The Journal of Biological Chemistry 2001, 276:14092-14099.
121. Mendes H.F., van der Spuy J., Chapple J.P., Cheetham M.E. Mechanisms of cell death in rhodopsin retinitis pigmentosa: Implications for therapy. Trends in Molecular Medicine 2005, 11:177-185.
122. Mercier J.F., Salahpour A., Angers S., Breit A., Bouvier M. Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. The Journal of Biological Chemistry 2002, 277:44925-44931.
123. Millar R.P. GnRH II and type II GnRH receptors. Trends in Endocrinology and Metabolism 2003, 14:35-43.
124. Millar R.P., Lu Z.L., Pawson A.J., Flanagan C.A., Morgan K., Maudsley S.R. Gonadotropin-releasing hormone receptors. Endocrine Reviews 2004, 25:235-275.
125. Millar R.P., Pawson A.J., Morgan K., Rissman E.F., Lu Z.L. Diversity of actions of GnRHs mediated by ligand-induced selective signaling. Frontiers in Neuroendocrinology 2008, 29:17-35.
126. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: A current perspective. Molecular Pharmacology 2003, 64:1271-1276.
127. Milligan G. G protein-coupled receptor dimerisation: Molecular basis and relevance to function. Biochimica et Biophysica Acta 2007, 1768:825-835.
128. Morello J.P., Bichet D.G. Nephrogenic diabetes insipidus. Annual Review of Physiology 2001, 63:607-630.
129. Nakamura M., Yasuda D., Hirota N., Shimizu T. Specific ligands as pharmacological chaperones: The transport of misfolded G-protein coupled receptors to the cell surface. IUBMB Life 2010, 62:453-459.
130. Naor Z. Signaling by G-protein-coupled receptor (GPCR): Studies on the GnRH receptor. Frontiers in Neuroendocrinology 2009, 30:10-29.
131. Nardai G., Vegh E.M., Prohaszka Z., Csermely P. Chaperone-related immune dysfunction: An emergent property of distorted chaperone networks. Trends in Immunology 2006, 27:74-79.
132. Ni M., Lee A.S. ER chaperones in mammalian development and human diseases. FEBS Letters 2007, 581:3641-3651.
133. Noorwez S.M., Kuksa V., Imanishi Y., Zhu L., Filipek S., Palczewski K., et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. The Journal of Biological Chemistry 2003, 278:14442-14450.
134. Noorwez S.M., Malhotra R., McDowell J.H., Smith K.A., Krebs M.P., Kaushal S. Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. The Journal of Biological Chemistry 2004, 279:16278-16284.
135. Noorwez S.M., Ostrov D.A., McDowell J.H., Krebs M.P., Kaushal S. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Investigative Ophthalmology & Visual Science 2008, 49:3224-3230.
136. Nowak R.J., Cuny G.D., Choi S., Lansbury P.T., Ray S.S. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. Journal of Medicinal Chemistry 2010, 53:2709-2718.
137. Ostrov D.A., Kaushai S., Noorwez S.M. Opsin stabilizing compounds and methods of use 2009, US Patent application number 20090286808.
138. Oueslati M., Hermosilla R., Schonenberger E., Oorschot V., Beyermann M., Wiesner B., et al. Rescue of a nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutant by cell-penetrating peptides. The Journal of Biological Chemistry 2007, 282:20676-20685.
139. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nature Reviews. Drug Discovery 2006, 5:993-996.
140. Petaja-Repo U.E., Hogue M., Laperriere A., Bhalla S., Walker P., Bouvier M. Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. The Journal of Biological Chemistry 2001, 276:4416-4423.
141. Petaja-Repo U.E., Hogue M., Laperriere A., Walker P., Bouvier M. Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor. The Journal of Biological Chemistry 2000, 275:13727-13736.
142. Pietila E.M., Tuusa J.T., Apaja P.M., Aatsinki J.T., Hakalahti A.E., Rajaniemi H.J., et al. Inefficient maturation of the rat luteinizing hormone receptor. A putative way to regulate receptor numbers at the cell surface. The Journal of Biological Chemistry 2005, 280:26622-26629.
143. Rab A., Bartoszewski R., Jurkuvenaite A., Wakefield J., Collawn J.F., Bebok Z. Endoplasmic reticulum stress and the unfolded protein response regulate genomic cystic fibrosis transmembrane conductance regulator expression. American Journal of Physiology. Cell Physiology 2007, 292:C756-C766.
144. Rana S., Besson G., Cook D.G., Rucker J., Smyth R.J., Yi Y., et al. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: Resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. Journal of Virology 1997, 71:3219-3227.
145. Reiche E.M., Bonametti A.M., Voltarelli J.C., Morimoto H.K., Watanabe M.A. Genetic polymorphisms in the chemokine and chemokine receptors: Impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Current Medicinal Chemistry 2007, 14:1325-1334.
146. Rivera V.M., Wang X., Wardwell S., Courage N.L., Volchuk A., Keenan T., et al. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science 2000, 287:826-830.
147. Robben J.H., Knoers N.V., Deen P.M. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model. American Journal of Physiology. Renal Physiology 2005, 289:F265-F272.
148. Robben J.H., Sze M., Knoers N.V., Deen P.M. Rescue of vasopressin V2 receptor mutants by chemical chaperones: Specificity and mechanism. Molecular Biology of the Cell 2006, 17:379-386.
149. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459:356-363.
150. Salahpour A., Angers S., Mercier J.F., Lagace M., Marullo S., Bouvier M. Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. The Journal of Biological Chemistry 2004, 279:33390-33397.
151. Saliba R.S., Munro P.M., Luthert P.J., Cheetham M.E. The cellular fate of mutant rhodopsin: Quality control, degradation and aggresome formation. Journal of Cell Science 2002, 115:2907-2918.
152. Sampedro J.G., Uribe S. Trehalose-enzyme interactions result in structure stabilization and activity inhibition. The role of viscosity. Molecular and Cellular Biochemistry 2004, 256-257:319-327.
153. Santen R.J., Bardin C.W. Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. The Journal of Clinical Investigation 1973, 52:2617-2628.
154. Sasaki S., Cho N., Nara Y., Harada M., Endo S., Suzuki N., et al. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: A highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. Journal of Medicinal Chemistry 2003, 46:113-124.
155. Schlyer S., Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discovery Today 2006, 11:481-493.
156. Schulein R., Zuhlke K., Krause G., Rosenthal W. Functional rescue of the nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutants G185C and R202C by a second site suppressor mutation. The Journal of Biological Chemistry 2001, 276:8384-8392.
157. Sitia R., Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 2003, 426:891-894.
158. Tanaka H., Moroi K., Iwai J., Takahashi H., Ohnuma N., Hori S., et al. Novel mutations of the endothelin B receptor gene in patients with Hirschsprung's disease and their characterization. The Journal of Biological Chemistry 1998, 273:11378-11383.
159. Tao Y.X. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Molecular and Cellular Endocrinology 2005, 239:1-14.
160. Tao Y.X. The melanocortin-4 receptor: Physiology, pharmacology, and pathophysiology. Endocrine Reviews 2010, 31:506-543.
161. Tao Y.X., Segaloff D.L. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology 2003, 144:4544-4551.
162. Terrillon S., Barberis C., Bouvier M. Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:1548-1553.
163. Thomas R.M., Nechamen C.A., Mazurkiewicz J.E., Muda M., Palmer S., Dias J.A. Follice-stimulating hormone receptor forms oligomers and shows evidence of carboxyl-terminal proteolytic processing. Endocrinology 2007, 148:1987-1995.
164. Tranchant T., Durand G., Gauthier C., Crepieux P., Ulloa-Aguirre A., Royere D., et al. Preferential beta-arrestin signalling at low receptor density revealed by functional characterization of the human FSH receptor A189 V mutation. Molecular and Cellular Endocrinology 2011, 331:109-118.
165. Trombetta E.S., Parodi A.J. Quality control and protein folding in the secretory pathway. Annual Review of Cell and Developmental Biology 2003, 19:649-676.
166. Uberti M.A., Hague C., Oller H., Minneman K.P., Hall R.A. Heterodimerization with beta2-adrenergic receptors promotes surface expression and functional activity of alpha1D-adrenergic receptors. The Journal of Pharmacology and Experimental Therapeutics 2005, 313:16-23.
167. Ulloa-Aguirre A., Conn P.M. G Protein-coupled receptors and the G protein family. Handbook of physiology, Section 7: The endocrine system, Vol. 1: Cellular endocrinology 1998, 87-124. Oxford University Press, New York. P.M. Conn (Ed.).
168. Ulloa-Aguirre A., Conn P.M. Targeting of G protein-coupled receptors to the plasma membrane in health and disease. Frontiers in Bioscience 2009, 14:973-994.
169. Ulloa-Aguirre A., Janovick J.A., Brothers S.P., Conn P.M. Pharmacologic rescue of conformationally-defective proteins: Implications for the treatment of human disease. Traffic 2004, 5:821-837.
170. Ulloa-Aguirre A., Janovick J.A., Leanos-Miranda A., Conn P.M. Misrouted cell surface receptors as a novel disease aetiology and potential therapeutic target: The case of hypogonadotropic hypogonadism due to gonadotropin-releasing hormone resistance. Expert Opinion on Therapeutic Targets 2003, 7:175-185.
171. Ulloa-Aguirre A., Janovick J.A., Leanos-Miranda A., Conn P.M. Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism. Human Reproduction Update 2004, 10:177-192.
172. Ulloa-Aguirre A., Janovick J.A., Miranda A.L., Conn P.M. G-protein-coupled receptor trafficking: Understanding the chemical basis of health and disease. ACS Chemical Biology 2006, 1:631-638.
173. Ulloa-Aguirre A., Stanislaus D., Janovick J.A., Conn P.M. Structure-activity relationships of G protein-coupled receptors. Archives of Medical Research 1999, 30:420-435.
174. Ulloa-Aguirre A., Timossi C. Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins. Reproductive Biomedicine Online 2000, 1:48-62.
175. White J.H., Wise A., Main M.J., Green A., Fraser N.J., Disney G.H., et al. Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 1998, 396:679-682.
176. Wuller S., Wiesner B., Loffler A., Furkert J., Krause G., Hermosilla R., et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. The Journal of Biological Chemistry 2004, 279:47254-47263.
177. Zarinan T., Perez-Solis M.A., Maya-Nunez G., Casas-Gonzalez P., Conn P.M., Dias J.A., et al. Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys. Molecular and Cell Endocrinology 2010, 321:112-122.
178. Zhang X.M., Wang X.T., Yue H., Leung S.W., Thibodeau P.H., Thomas P.J., et al. Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator. The Journal of Biological Chemistry 2003, 278:51232-51242.
179. Zhu X., Wess J. Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. Biochemistry 1998, 37:15773-15784.